Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/virtus-health-ltd" target="_blank" data-smartkarma-citation="entities:14776:1" rel="noopener">Virtus Health (VRT AU)</a> gives the nod to CapVest as the latter bumps to $8.25/share - less dividends - by way of a Scheme</li>
<li>CapVest will also make a concurrent off-market takeover Offer at $8.10, less dividends. This Offer can be triggered if the first Offer fails, and would only require 50.1% shareholder approval.</li>
<li>Trading one spread below CapVest's firm Scheme terms. Back in BGH's court. Again.</li>
</ul>



Virtus Health (VRT AU) gives the nod to CapVest as the latter bumps to $8.25/share - less dividends - by way of a Scheme
CapVest will also make a concurrent off-market takeover Offer at $8.10, less dividends. This Offer can be triggered if the first Offer fails, and would only require 50.1% shareholder approval.
Trading one spread below CapVest's firm Scheme terms. Back in BGH's court. Again.


Virtus Enters Into Firm Deal With CapVest

<ul>
<li>CapVest was clearly prepared. One day after <a href="https://www.smartkarma.com/entities/virtus-health-ltd" target="_blank" data-smartkarma-citation="entities:14776:1" rel="noopener">Virtus Health (VRT AU)</a> received a revised non-binding bid from BGH Capital of $7.65/share, CapVest bumped to $7.80 by way of a Scheme.</li>
<li>An off-market takeover bid with a minimum 50.1% minimum acceptance condition, offering $7.70/shares was also tabled by CapVest. </li>
<li>Virtus has pivoted to CapVest and will not engage with BGH as to its A$7.65/share Offer.</li>
</ul>


CapVest was clearly prepared. One day after Virtus Health (VRT AU) received a revised non-binding bid from BGH Capital of $7.65/share, CapVest bumped to $7.80 by way of a Scheme.
An off-market takeover bid with a minimum 50.1% minimum acceptance condition, offering $7.70/shares was also tabled by CapVest. 
Virtus has pivoted to CapVest and will not engage with BGH as to its A$7.65/share Offer.


Virtus Health Backs CapVest's Revised Bid

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

<ul>
<li>BGH’s revised scheme offer will pay $7.65 per <a href="https://www.smartkarma.com/entities/virtus-health-ltd" target="_blank" data-smartkarma-citation="entities:14776:1" rel="noopener">Virtus Health (VRT AU)</a> share, which is 0.7% and 2.0% higher than CapVest’s rival scheme (A$7.60) and off-market takeover offer (A$7.50), respectively.</li>
<li>BGH (19.99% stake) will vote against the CapVest scheme and will not accept any takeover offer from CapVest. Consequently, CapVest’s best option is an improved off-market takeover bid.</li>
<li>As CapVest's offer is marginally below BGH's revised offer, CapVest retains the potential to lob an improved offer, in our view.</li>
</ul>


BGH’s revised scheme offer will pay $7.65 per Virtus Health (VRT AU) share, which is 0.7% and 2.0% higher than CapVest’s rival scheme (A$7.60) and off-market takeover offer (A$7.50), respectively.
BGH (19.99% stake) will vote against the CapVest scheme and will not accept any takeover offer from CapVest. Consequently, CapVest’s best option is an improved off-market takeover bid.
As CapVest's offer is marginally below BGH's revised offer, CapVest retains the potential to lob an improved offer, in our view.


<ul>
<li>Fertility specialist <a href="https://www.smartkarma.com/entities/virtus-health-ltd" target="_blank" data-smartkarma-citation="entities:14776:1" rel="noopener">Virtus Health (VRT AU)</a> has received a revised non-binding <a href="https://www.smartkarma.com/compose/insight/66126/Vinva%20became%20a%20substantial%20shareholder%20on%20the%2022%20November." target="_blank" rel="noopener">takeover bid</a> from BGH Capital of $7.65/share, less any dividends declared by Virtus. It had previously offered $7.10/share.</li>
<li>BGH also said it would vote its 19.99% stake against CapVest Partners' cash offer of $7.60/share. </li>
<li>Back in CapVest's court. A $0.05/share higher bid is unlikely to see the UK-based player fold its tent.</li>
</ul>


Fertility specialist Virtus Health (VRT AU) has received a revised non-binding takeover bid from BGH Capital of $7.65/share, less any dividends declared by Virtus. It had previously offered $7.10/share.
BGH also said it would vote its 19.99% stake against CapVest Partners' cash offer of $7.60/share. 
Back in CapVest's court. A $0.05/share higher bid is unlikely to see the UK-based player fold its tent.


<ul>
<li>BGH has filed an <a href="https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02482688_PS-2A1354502?access_token=83ff96335c2d45a094df02a206a39ff4" target="_blank" rel="noopener">application</a> with the Takeover Panel over, inter alia, <a href="https://www.smartkarma.com/entities/virtus-health-ltd" target="_blank" data-smartkarma-citation="entities:14776:1" rel="noopener">Virtus Health (VRT AU)</a> granting exclusivity to CapVest.</li>
<li>This application is similar in nature to the one filed by <a href="https://www.smartkarma.com/entities/apa-group" target="_blank" data-smartkarma-citation="entities:18658:1" rel="noopener">APA Group (APA AU)</a> last year after <a href="https://www.smartkarma.com/entities/ausnet-services" target="_blank" data-smartkarma-citation="entities:10293:1" rel="noopener">AusNet Services (AST AU)</a> granted Brookfield exclusivity in a competitive bidding stoush.</li>
<li>Virtus is currently trading at a gross spread of ~5.0% to the Scheme price, 3.6% to the Alternative Offer, and 1.8% above BGH's terms. </li>
</ul>


BGH has filed an application with the Takeover Panel over, inter alia, Virtus Health (VRT AU) granting exclusivity to CapVest.
This application is similar in nature to the one filed by APA Group (APA AU) last year after AusNet Services (AST AU) granted Brookfield exclusivity in a competitive bidding stoush.
Virtus is currently trading at a gross spread of ~5.0% to the Scheme price, 3.6% to the Alternative Offer, and 1.8% above BGH's terms. 


BGH Lodges Application With The Takeovers Panel Over CapVest's Bid for Virtus

Australia

Virtus Health Limited provides health care services. The Company offers clinical, scientific, diagnostic services, and day surgery for reproductive and fertility health care. Virtus Health serves patients and operates reproductive health and fertility clinics throughout eastern Australia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Virtus Health (VRT AU)

Virtus Enters Into Firm Deal With CapVest

Trading one spread below CapVest's firm Scheme terms. It's possible BGH reloads. Or folds. Entering around here appears attractive. Plus there is a...

David Blennerhassett

Virtus Health Backs CapVest's Revised Bid

Trading at a gross spread of ~1.2% to CapVest's Scheme proposal, and 0.13% above the off-market terms. This remains a buy here. Get long or stay...

David Blennerhassett

BGH’s Revised Higher Offer for Virtus

BGH has returned with a revised offer of $7.65 per share, which is 7.7% higher than BGH’s original offer of A$7.10. CapVest’s (rival suitor) best...

Arun George

BGH Ups The Ante For Control Of Virtus

Trading at a reasonably attractive gross spread of ~2.4% to the latest proposal. BGH's Offer adds just A$4mn to the consideration payout versus...

David Blennerhassett

BGH Lodges Application With The Takeovers Panel Over CapVest's Bid for Virtus

Both proposals (BGH and CapVest's) are indicative - for now. Trading at a gross spread of ~5.0% to the Scheme price, 3.6% to the Alternative Offer,...

David Blennerhassett

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)